EN DE
Watch Strata Critical Medical, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Strata Critical Medical, Inc. (SRTA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Strata Critical Medical, Inc. stock $4.50, price $5.42, that is 17.0% below the price, quality 46 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US0926671043

SC Strata Critical Medical, Inc. logo Thin data Nov 17, 2026

Strata Critical Medical, Inc.

SRTA · US

Expensive (fair value 17% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Revenue last quarter +50% vs. a year ago. 
Quality 46/100 
Price moving sideways (no uptrend) 
Expensive Growth (revenue 5y +53.1 %/yr in USD) 
Recent news mixed 
Insiders bought $9,998 (6M) · sold $749,036 
Fair value $4.50 · Overvalued 
Loss-making · -8.8% net margin (TTM) 
Negative free cash flow 
Trails peers (2/10) 
Narrow moat 12/100
Thin data 
Estimate
Watch Strata Critical Medical, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$11.63 $2.08 Fair Value $4.50 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $2.08 – $11.63 · fair‑value band $3.37 – $5.62 · the $5.42 price screens above the $4.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Strata Critical Medical in your weekly email

Every Wednesday you see whether Strata Critical Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Strata Critical Medical, Inc. provides time-critical logistics and medical services to the healthcare industry in the United States. It operates in two segments, Logistics and Clinical.

Show moreShow less

The company offers logistics services, such as air and ground transportation for human organs, transplant teams, and related medical materials and organ placement services; transplant clinical services, including organ recovery procedures, normothermic regional perfusion, and preservation services.

It also provides other clinical services comprising cardiac perfusion services, blood management and autotransfusion services, extracorporeal membrane oxygenation services, perfusion staffing, and equipment rentals.

The company was formerly known as Blade Air Mobility, Inc. and changed its name to Strata Critical Medical, Inc. in August 2025. The company was founded in 2014 and is headquartered in New York, New York.

Stock analysis

Strata Critical Medical, Inc. (SRTA) currently trades at $5.42, while our estimate is $4.50, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $3.37 (bear) to $5.62 (bull), the price of $5.42 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Strata Critical Medical, Inc. reported revenue of $197M in FY2025 versus $50.5M in FY2021, a compound +40.5%/yr. Reported net income was −$15.6M in FY2025.

Key figures

Market cap $487M Small · P/S ratio 1.92 · EPS (TTM) $−0.2400 · Net margin −8.8% · Return on equity −7.6% · Return on assets (EBIT) −12.6% (5-year average) · Operating margin −4.3% · Revenue (TTM) $281M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 16% below its 52-week high and 34% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −17%, SRTA screens richer than that median.

Fair Value

Bear $3.37 Fair Value $4.50 Bull $5.62
Price $5.42 · Downside -17.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 83
Debt, balance sheet and risk of trouble
Investment 92
Does it invest with discipline instead of growing at any price?
Low Volatility 4
How calm the share price moves, does not count
Price momentum 36
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 51
Distance to the 52-week high, does not count
New shares 30
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $9,998, on Nov 5, 2026. Over the same period, 5 people sold shares worth $749,036.

  • BuyAndrew LauckDirector2× since Dec 5, 2025: 7,000 shares, avg. $4.55$31,848Nov 5, 2026
  • SaleReginald LoveDirector3× since Nov 19, 2025: 27,091 shares, avg. $4.60$124,753Aug 10, 2026
  • SaleScott M WunschCEO, Logistics5,550 shares at $5.87$32,579Jun 8, 2026
  • SaleMelissa M. TomkielCo-CEO and General Counsel, Director29,730 shares at $5.87$174,515Jun 8, 2026
  • SaleAmir CohenChief Accounting Officer3× since May 11, 2026: 69,836 shares, avg. $5.87$409,592Jun 8, 2026
  • SaleWilliam A. HeyburnCo-CEO and CFO, Director31,671 shares at $5.87$185,909Jun 8, 2026
  • BuyWilliam A. HeyburnCo-CEO and CFO, Director17,000 shares at $4.47$75,990Dec 9, 2025

Plus 21 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−20.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−44.2% (2020) → −5.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SRTA screens overvalued: fair value 17% below the price. Compare with HCA Healthcare, Inc →

Earlier news

News mood ⓘNews mood, the average tone of recent news (45 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Strata Critical Medical, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 248 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside −17.0% · Below median
Profitability
Return on assets −4.8% · Bottom 25%
Net margin (12 months) −8.8% · Bottom 25%
Operating margin (12 months) −4.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 50.3% · Top 25%

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 1.75× · Cheaper than median
P/S (12 months) 1.74× · Pricier than median
EV/EBITDA 52.0× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 34
FUTURE (revenue growth)100 · sector 33
PAST (return on equity)0 · sector 32
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)0 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $21.86 $45.73 +109% vs SRTA
DaVita Inc DVA $174.22 $218.90 +26% vs SRTA
Aier Eye Hospital Group 300015 ¥9.15 ¥10.88 +19% vs SRTA
HCA Healthcare, Inc HCA $511.78 $547.34 +7% vs SRTA
Tenet Healthcare Corporation THC $291.54 $279.20 −4% vs SRTA
The Ensign Group ENSG $188.23 $140.09 −26% vs SRTA
Encompass Health Corporation EHC $142.11 $94.81 −33% vs SRTA
Fresenius SE FRE €53.75 €34.77 −35% vs SRTA
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,713 ₹5,234 −40% vs SRTA
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs SRTA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Strata Critical Medical, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Strata Critical Medical, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/SRTA

Frequently asked questions

Is Strata Critical Medical, Inc. (SRTA) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $4.50 versus a price of $5.42, about 17% lower (overvalued).
What is the fair value of SRTA?
Our estimate for Strata Critical Medical, Inc. is $4.50 (as of Nov 17, 2026), built from audited fundamentals. The current price: $5.42.
What is the quality score of SRTA?
Strata Critical Medical, Inc. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Strata Critical Medical, Inc. (SRTA)?
Our calculated price target is the estimate of $4.50 (as of Nov 17, 2026). Cautious scenario $3.37, optimistic scenario $5.62. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Strata Critical Medical, Inc. stock forecast for 2026?
Our estimate puts fair value at $4.50, about 17% lower versus a price of $5.42 (overvalued). Cautious scenario $3.37, optimistic scenario $5.62. The calculation is refreshed regularly with new filings.
What is the revenue of Strata Critical Medical, Inc. (SRTA)?
Strata Critical Medical, Inc. reported trailing-twelve-month revenue of about $281M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Strata Critical Medical, Inc. (SRTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Strata Critical Medical, Inc. it is $4.50 per share (as of Nov 17, 2026), against a price of $5.42.
Is Strata Critical Medical, Inc. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, SRTA trades above its calculated fair value: price $5.42, fair value $4.50, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SRTA?
No. The price is what the market pays today ($5.42); the fair value is what the company's own numbers justify ($4.50). For Strata Critical Medical, Inc. the two are $0.9200 per share apart. That gap is exactly why we show both numbers side by side.
How much is Strata Critical Medical, Inc. worth?
The market values Strata Critical Medical, Inc. at about $487M (market capitalisation, as of Nov 17, 2026). Per share that is $5.42; our models calculate a fair value of $4.50 per share.
What do the bullish and bearish scenarios say about SRTA?
Our models span a range for Strata Critical Medical, Inc.: cautious scenario $3.37, base $4.50, optimistic $5.62 per share (as of Nov 17, 2026, price $5.42). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Strata Critical Medical, Inc. (SRTA)?
Balance-sheet figures for Strata Critical Medical, Inc. (as of Nov 17, 2026): return on equity −7.6%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is SRTA from its 52-week high?
Strata Critical Medical, Inc. trades at $5.42, about 16% below its 52-week high of $6.47 and 34% above the low of $4.03 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $4.50 is for.
Which stocks are comparable to Strata Critical Medical, Inc.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Strata Critical Medical, Inc. stock attractive at the current price?
The data as of Nov 17, 2026: price $5.42, calculated fair value $4.50 (−17%), Quality Score 46/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Strata Critical Medical, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Strata Critical Medical, Inc. (SRTA)?
The closing price on Nov 16, 2026 was $5.42. Our estimate is $4.50, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Strata Critical Medical, Inc. right now?
Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Strata Critical Medical, Inc.

How large is the market capitalisation of Strata Critical Medical, Inc. (SRTA)?
The market capitalisation of Strata Critical Medical, Inc. is $487M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Strata Critical Medical, Inc. (SRTA)?
The price-to-sales ratio of Strata Critical Medical, Inc. is 1.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Strata Critical Medical, Inc. (SRTA)?
Earnings per share at Strata Critical Medical, Inc. are $−0.2400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Strata Critical Medical, Inc. (SRTA)?
The net margin of Strata Critical Medical, Inc. is −8.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Strata Critical Medical, Inc. (SRTA)?
The return on equity (ROE) of Strata Critical Medical, Inc. is −7.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Strata Critical Medical, Inc. (SRTA)?
On an EBIT basis the return on assets of Strata Critical Medical, Inc. is −12.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Strata Critical Medical, Inc. (SRTA)?
The operating margin of Strata Critical Medical, Inc. is −4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Strata Critical Medical, Inc. (SRTA)?
Revenue at Strata Critical Medical, Inc. is growing 50.3% versus a year earlier (3y avg +10.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Strata Critical Medical, Inc. (SRTA) generate?
The free cash flow of Strata Critical Medical, Inc. is −$59.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Strata Critical Medical, Inc. (SRTA) hold?
Strata Critical Medical, Inc. holds more cash than debt, $27.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Strata Critical Medical, Inc. in the live analysis

One click puts Strata Critical Medical, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.